Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership ...

Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

Kostas Biliouris, an analyst from BMO Capital, maintained the Buy rating on Metagenomi, Inc. (MGX – Research Report). The associated ...

Enhances strategic flexibility and control of key gene editing technologies and programsEMERYVILLE, Calif., May 01, 2024 ...

Real estate companies PH1 World Developers (PH1WD) and ProFriends recently formalized a development contract for their joint venture Famtech Properties (Famtech). Famtech will develop One Lancaster ...

The number of homes that sold for more than $1 million in the region declined from 2022 to 2023, according to ICE Mortgage ...

Clouding over through today with spells of rain soon moving in from the east. The rain could become wintry over the highest hills. Tonight Tonight will see any clouds and rain move off to the ...

Study discusses the potential of universal influenza vaccines, emphasizing the importance of antibody breadth and Fc receptor ...

THE Philippines remains vulnerable to climate change threats with its impact estimated to exceed P637 billion in the coming ...

The Lamudi Property Fair returns to TriNoma for the Metro Manila leg of the country’s biggest property expo. It brings top ...

BOSTON 300 Pier 4 Blvd #7C Condo mid-rise, built in 2017, 2,255 square feet, 6 rooms, 3 bedrooms, 4 baths. $6,550,000 ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...